Nikolay V. Demin

Nikolay V. Demin

Auto-generated profile, based on publicly available information

Nikolay V. Demin

Nasonova Research Institute of Rheumatology

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2022 in Rheumatology Science and Practice
Verified
Journal Article
Open access
PDF file
ASA. O. Sorokina
A. O. Sorokina
NDN. V. Demin
N. V. Demin
ODO. V. Dobrovolskaya
O. V. Dobrovolskaya
ONO. A. Nikitinskaya
O. A. Nikitinskaya
NTN. V. Toroptsova
N. V. Toroptsova
AFA. Yu. Feklistov
A. Yu. Feklistov
Aim – to identify the frequency of isolated and combined pathological phenotypes of body composition in women with rheumatic diseases and to determine the factors associated with the sarcopenic phenotype.Materials and methods. 255 women (median age 60 [54; 64] years) were included in the study: 114 patients with rheumatoid arthritis (RA), 46 – with systemic sclerosis (SSc), 56 – with osteoarthritis (OA), and 39 persons without rheumatic diseases (control). Questionnaires, anthropometric measurements, double-energy X-ray absorptiometry of the whole body, lumbar spine and proximal femur were performed. The assessment of the factors associated with the sarcopenic phenotype was carried out using a univariate regression analysis.Results. The frequency of isolated and combined pathological phenotypes in women with SSc was 34.8% and 52.2%, with RA – 51.8% and 38.6%, with OA – 71.4% and 10.7%, respectively. The sarcopenic phenotype was more often determined in patients with SSc (43.5%) and RA (29.8%) compared with women with OA (1.8%) (p˂ 0.001). The factors associated with the sarcopenic phenotype were BMI˂ 25 kg/m2 (OR=7.89 [95% CI: 3.90–15.96]; p˂ 0.001), glucocorticoids (GC) intake (OR=2.50 [95% CI: 1.32–4.73]; p=0.005) and cumulative GC dose (OR=1.04 [95% CI: 1.01–1.07]; p=0.008), presence of osteoporosis (OP) (OR=4.31 [95% CI: 2.33–7.97]; p˂ 0.001), leukocytosis more than 9.0×109 /l (OR=4.08 [95% CI: 1.38–12.10]; p=0.011), total protein less than 65 g/l (OR=1.11 [95% CI: 1.02–1.19]; p=0.019) and calcium intake less than 500 mg/day (OR=2.78 [95% CI: 1.39–5.53]; p=0.004).Conclusion. The study demonstrated a significant frequency of pathological phenotypes of body composition in women with rheumatic diseases, while combined phenotypes were more common in patients with SSc and RA compared with patients with OA. The probability of sarcopenic phenotype increased with BMI˂ 25 kg/m2, GC using, the presence of OP and insufficiency of calcium intake.

17 April 2020 in Pharmateca
Verified
Journal Article
Closed access
ODO.V. Dobrovolskaya Dobrovolskaya
O.V. Dobrovolskaya Dobrovolskaya
NTN.V. Toroptsova Toroptsova
N.V. Toroptsova Toroptsova
NDN.V. Demin Demin
N.V. Demin Demin
AFA.YU. Feklistov Feklistov
A.YU. Feklistov Feklistov
ONO.A. Nikitinskaya Nikitinskaya
O.A. Nikitinskaya Nikitinskaya

18 February 2021 in Modern Rheumatology Journal
Verified
Journal Article
Open access
PDF file
AEA. О. Efremova
A. О. Efremova
NTN. V. Toroptsova
N. V. Toroptsova
ODO. V. Dobrovolskaya
O. V. Dobrovolskaya
NDN. V. Demin
N. V. Demin
ONO. A. Nikitinskaya
O. A. Nikitinskaya
Objective: to estimate the high and very high Frax® 10-year probabilities of fractures in patients with systemic sclerosis (SSc) to assess the need for anti-osteoporotic treatment.Patients and methods. The investigation enrolled 136 SSc patients (110 women and 26 men; mean age, 59.3±7.5 years). The patients underwent a questionnaire survey, by calculating the risk of major fractures with the FRAX® algorithm and dual-energy X-ray densitometry (DXA) of the lumbar spine and proximal femur.Results and discussion. There was a very high risk of fractures in 41.2% of the examinees, a high risk in 10.3%, and a low risk in 48.5%. Osteoporosis (OP) in at least one area was detected in 41.2% of the patients. Among the persons with a low risk of fractures, OP was diagnosed in 18.2%, whereas 10.6% had a history of fractures. A total of 65.4% of SSc patients needed anti-osteoporotic treatment.Conclusion. According to the comprehensive assessment, OP treatment and fracture prevention were indicated for 65.4% of SSc patients. The FRAX® algorithm is less informative in males who need therapy than in females.

1 June 2018 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
AFA. Feklistov
A. Feklistov
NDN. Demin
N. Demin
NTN. Toroptsova
N. Toroptsova
Background Rheumatoid arthritis (RA) is a systemic inflammatory disease associated with polyarthritis, progressive joint damage, and physical impairment that can lead to osteoporosis and sarcopenia, increasing the risk of fractures and leading to a greater loss of autonomy in RA patients. Objectives To assess frequency of osteoporosis, sarcopenia and osteosarcopenia in women with RA. Methods 40 female patients with RA (mean age 63±7 years) and 40 female controls without RA (mean age 64±9 years) were enrolled in this study. Body composition and bone mineral density (BMD) in lumbar spine and proximal hip were assessed by using dual X-ray absorptiometry (DXA, Hologic Discovery A). Sarcopenia in women was defined as a skeletal muscle index (SMI) ≤5.67 kg/m21 and osteosarcopenia – if sarcopenia and low BMD were present together.2 The participants performed Short Physical Performance Battery (SPPB) and handgrip strength was measured. Body mass index (BMI) and Disease Activity Score (DAS28) were calculated. Results Low BMD at least in one of measured area was found out in 19 (48%) RA persons and in 18 (45%) controls. Sarcopenia occurred in 10 (25%) RA patients and in 5 (12,5%) people without RA (p>0,05). Among them osteosarcopenia was found in 6 (15%) RA women and 2 (5%) controls. Skeletal muscle index (SMI) was lower in patients with RA (6.43±0.978) than in controls (7.01±1. 064, p<0,05). In RA patients SMI had a positive correlation with BMI (r=0,58, p<0,05) and handgrip strength (r=0,34 for right, r=0,30 for left, p<0.05 for both). Sarcopenia was more common in RA patients who were normal or underweight than in those who were overweight or obese according to their BMI (p<0.01). There was no correlation between SMI and DAS28, drug use, frequency of falls during the last year, SPPB in the RA group Conclusions In RA patients 48% had osteoporosis and 25% – sarcopenia, among them 15% women – osteosarcopenia. The risk of sarcopenia and osteosarcopenia was higher in nonobese patients. References [1] Cruz-Jentoft AJ, et al. Sarcopenia: European consensus on definition and diagnosis. Age and Agening2010;39:412–423. [2] Hassan EB, Duque G. Osteosarcopenia: A new geriatric syndrome. Aust Fam Physician2017Nov;46(11):849–853. Disclosure of Interest None declared

6 May 2022 in Modern Rheumatology Journal
Verified
Journal Article
Open access
PDF file
NTN. V. Toroptsova
N. V. Toroptsova
AEA. O. Efremova
A. O. Efremova
TKT. A. Korotkova
T. A. Korotkova
ODO. V. Dobrovolskaya
O. V. Dobrovolskaya
NDN. V. Demin
N. V. Demin
MCMARIA CHERKASOVA
MARIA CHERKASOVA
Objective: to evaluate the effect of the generic drug of zoledronic acid on bone mineral density (BMD) and markers of bone metabolism in patients with osteoporosis (OP), as well as possible long-term adverse reactions (AR) 12 months after drug administration.Patients and methods. The study included 30 postmenopausal women with OP (mean age 64±8 years) who signed an informed consent of participance in clinical observation. Patients received a single dose of generic zoledronic acid (5 mg) as a 15-minute infusion. All patients additionally took calcium and vitamin D. The dynamics of BMD and bone metabolism markers, as well as the safety and tolerability of the drug, were evaluated. Fractures that might have occurred during follow-up should have been reported as ARs.Results and discussion. During treatment with generic zoledronic acid, the increase in BMD in the lumbar region was 4.9% (p<0.0001), in the femoral neck –2.7% (p<0.01), and in the femur as a whole – 3.0% (p2%) in the spine was detected in 26 (86.7%) patients, in the proximal femur – in 20 (66.7%) patients. There was a decrease in the intensity of pain in both the thoracic (by 62%; p=0.038) and lumbar (by 29%; p=0.022) spine. Three months after the administration of the drug, a decrease in the level of bone metabolism markers was revealed: CTX – by an average of 29.7%, and P1NP – by an average of 25.5%. ARs were post-dose reactions that occurred within the first 48 hours after drug infusion. Remote ARs, fractures of peripheral bones and vertebrae were not recorded.Conclusion. The use of the generic drug of zoledronic acid has demonstrated its positive effect on BMD and markers of bone metabolism, as well as safety.

17 June 2022 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
ODOlga V. Dobrovolskaya
Olga V. Dobrovolskaya
NTNatalia V. Toroptsova
Natalia V. Toroptsova
AFAlexey Yu. Feklistov
Alexey Yu. Feklistov
NDNikolay V. Demin
Nikolay V. Demin
ASArina O. Sorokina
Arina O. Sorokina
ТВТоропцова Наталья Владимировна
Торопцова Наталья Владимировна
Aim. To evaluate the frequency of different body composition phenotypes, physical performance (PP) and their relationship with quality of life in women with rheumatoid arthritis (RA). Materials and methods. The study included 157 women (average age 58.68.8 years) with RA. Clinical and laboratory examination, dual-energy X-ray absorptiometry, quality of life assessment according to the questionnaires EQ-5D (European Quality of Life Questionnaire), HADS (Hospital Anxiety and Depression Scale) and RAID (Rheumatoid Arthritis Impact of Disease), determination of muscle strength and the PP of skeletal muscles were carried out. Results. Osteoporotic, sarcopenic and osteosarcopenic phenotypes of body composition were identified in 27 (17%), 16 (10%) and 16 (10%) patients, respectively; 139 (88.5%) people had low muscle strength, and 96 (61.1%) had reduced PP. Quality of life according to the EQ-5D index and RAID, the severity of depression according to HADS in women with different phenotypes of body composition did not differ. Women with osteosarcopenic phenotype had worse indicators for EQ-5D-VAS (VAS visual analog scale), and patients with sarcopenic phenotype had more severe anxiety according to the HADS questionnaire compared to those with normal phenotype (p=0.014 and p=0.027, respectively). The quality of life according to all questionnaires was significantly worse in patients with reduced PP. Conclusion. Pathological phenotypes of body composition were found in 37% of RA patients. A decrease in muscle strength was revealed in 88.5%, and a low PP in 61.1% of patients. The relationship between quality of life and body composition has not been established, at the same time quality of life associated with the PP of skeletal muscles.